MA54903A - Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1 - Google Patents

Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1

Info

Publication number
MA54903A
MA54903A MA054903A MA54903A MA54903A MA 54903 A MA54903 A MA 54903A MA 054903 A MA054903 A MA 054903A MA 54903 A MA54903 A MA 54903A MA 54903 A MA54903 A MA 54903A
Authority
MA
Morocco
Prior art keywords
il18r1
kits
compositions
methods
inflammatory disease
Prior art date
Application number
MA054903A
Other languages
English (en)
Inventor
Janine Bilsborough
Dermot P Mcgovern
Stephan R Targan
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of MA54903A publication Critical patent/MA54903A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054903A 2019-02-08 2020-02-07 Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1 MA54903A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802828P 2019-02-08 2019-02-08
US201962815223P 2019-03-07 2019-03-07

Publications (1)

Publication Number Publication Date
MA54903A true MA54903A (fr) 2021-12-15

Family

ID=71947518

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054903A MA54903A (fr) 2019-02-08 2020-02-07 Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1

Country Status (12)

Country Link
US (1) US20220056106A1 (fr)
EP (1) EP3920953A4 (fr)
JP (1) JP2022519819A (fr)
KR (1) KR20210130168A (fr)
CN (1) CN113645991A (fr)
AU (1) AU2020217793A1 (fr)
BR (1) BR112021015222A2 (fr)
CA (1) CA3127962A1 (fr)
IL (1) IL285344A (fr)
MA (1) MA54903A (fr)
MX (1) MX2021009247A (fr)
WO (1) WO2020163715A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CA3121162A1 (fr) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Compositions de rnaset2 et methodes de traitement les utilisant
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
JP2025508823A (ja) 2022-02-23 2025-04-10 ブライト ピーク セラピューティクス エージー 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用
US20250218534A1 (en) * 2022-08-05 2025-07-03 Illumina, Inc. Artificial intelligence-based epigenetics at base resolution
WO2025219338A1 (fr) 2024-04-15 2025-10-23 Universität Zürich Inhibiteurs de card9 et leur utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
EP1808446B1 (fr) * 2004-07-16 2012-01-18 Atsuo Sekiyama Antagoniste du recepteur il-18 et composition pharmaceutique contenant cet antagoniste
US8367333B2 (en) * 2008-12-12 2013-02-05 Decode Genetics Ehf. Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction
KR20180127416A (ko) * 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
WO2019209942A1 (fr) * 2018-04-24 2019-10-31 Cedars-Sinai Medical Center Méthodes et systèmes de caractérisation de maladie de crohn grave
MA52251A (fr) * 2018-04-30 2021-02-17 Cedars Sinai Medical Center Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires
WO2020014650A1 (fr) * 2018-07-13 2020-01-16 Memorial Sloan Kettering Cancer Center Méthodes d'utilisation d'inhibiteurs pharmacologiques de la signalisation des cytokines de type 2 pour traiter ou prévenir le cancer du pancréas

Also Published As

Publication number Publication date
EP3920953A4 (fr) 2022-12-14
CA3127962A1 (fr) 2020-08-13
BR112021015222A2 (pt) 2021-12-28
KR20210130168A (ko) 2021-10-29
EP3920953A1 (fr) 2021-12-15
MX2021009247A (es) 2021-09-08
WO2020163715A1 (fr) 2020-08-13
JP2022519819A (ja) 2022-03-25
IL285344A (en) 2021-09-30
AU2020217793A1 (en) 2021-09-30
US20220056106A1 (en) 2022-02-24
CN113645991A (zh) 2021-11-12

Similar Documents

Publication Publication Date Title
EP3920953A4 (fr) Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1
JOP20200115A1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3534907A4 (fr) Compositions et méthodes de traitement d'une maladie hépatique
EP3897747A4 (fr) Molécules bi-fonctionnelles pour le ciblage des lysosomes, compositions et méthodes associées
EP3852608A4 (fr) Compositions et méthodes destinées à traiter le glaucome
MX2021006053A (es) Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
MA56212A (fr) Compositions et méthodes de traitement du cancer
EP3817771A4 (fr) Compositions et méthodes pour traiter une maladie intestinale inflammatoire
EP3952914A4 (fr) Procédés et compositions pour une dégradation de protéine ciblée
MA52208A (fr) Biomarqueurs pour une maladie du greffon contre l'hôte
EP3678640A4 (fr) Procédés et compositions pour traiter une maladie cutanée inflammatoire
EA202092086A1 (ru) Ингибиторы аргиназы
WO2018098117A8 (fr) Compositions à base d'arni ciblant le gène serpina1 et leurs méthodes d'utilisation
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
EA201592223A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
EP3442502A4 (fr) Compositions, systèmes, kits et méthodes pour traiter une infection
EP3768270A4 (fr) Méthodes et compositions pour traiter une fibrose pulmonaire idiopathique
EA201070127A1 (ru) Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления
EP3891274A4 (fr) Compositions et méthodes pour traiter une déficience en ornithine transcarbamylase
EP3500257A4 (fr) Composés inhibiteurs de kinase, compositions et méthodes de traitement du cancer
EP3958878A4 (fr) Méthodes de conditionnement pour thérapie génique
EP4110822A4 (fr) Compositions et méthodes pour traiter le cancer